APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00523315
- Lead Sponsor
- AstraZeneca
- Brief Summary
To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 862
Inclusion Criteria
-
Provision of written informed consent
-
Patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice
-
Histologically or cytologically proven to be HR+(ER or PR +)
-
Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline):
- Age >= 50 years
- Age < 50 years with amenorrhoea > 12 months and an intact uterus
- FSH levels within postmenopausal range (over 30-40 IU/ml), or
- Having undergone a bilateral oophorectomy.
- No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
Read More
Exclusion Criteria
- Recurrence of breast cancer
- Known hypersensitivity to aromatase inhibitor or to any of the excipients
- Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol
- Previous inclusion in the present study
- Participation in a clinical study during the last 30 days
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Reserach Site
🇰🇷Euijungbu-si, Gyunggi-do, Korea, Republic of
Research Site
🇰🇷Ulsan, Korea, Republic of